Johnson & Johnson announced that RYBREVANT combined with chemotherapy significantly improved overall survival in patients with advanced non-small cell lung cancer (NSCLC) harboring EGFR exon 20 insertion mutations. The Phase 3 PAPILLON study showed a median overall survival of 34.3 months with the combination, compared to 27.9 months with chemotherapy alone, nearly doubling historical survival rates. This dual-targeting treatment addresses a patient group with limited options and poor prognosis, marking a major advance in lung cancer therapy. The results support RYBREVANT's role as a first-line treatment and ongoing research aims to improve patient experience and outcomes further.
Five Dividend Kings—Procter & Gamble, Johnson & Johnson, Lowe’s, Emerson Electric, and Genuine Parts Company—are highlighted as top income stocks for retirees due to their decades-long records of annual dividend increases. These companies have mainta...
The iShares U.S. Pharmaceuticals ETF (IHE) provides focused exposure to the US pharmaceutical sector, heavily weighted towards Johnson & Johnson and Eli Lilly. It benefits from growth drivers like obesity therapies and strong drug pipelines but carri...
Five dividend stocks—Procter & Gamble, Johnson & Johnson, Coca-Cola, Colgate-Palmolive, and PepsiCo—have consistently raised their dividends through every U.S. recession since at least 1963. These companies demonstrated resilience during major downtu...
The iShares US Pharmaceuticals ETF (IHE) is rated a hold due to fair valuation and increasing short-term challenges. Its portfolio is heavily concentrated, with 43% in Johnson & Johnson and Eli Lilly, and the top 10 holdings making up 76%. Technical ...
